

C

=&gt; fil medline

FILE 'MEDLINE' ENTERED AT 13:37:08 ON 03 JUL 2006

FILE LAST UPDATED: 1 JUL 2006 (20060701/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).

See also:

<http://www.nlm.nih.gov/mesh/>  
[http://www.nlm.nih.gov/pubs/techbull/nd04/nd04\\_mesh.html](http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html)  
[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_med\\_data\\_changes.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html)  
[http://www.nlm.nih.gov/pubs/techbull/nd05/nd05\\_2006\\_MeSH.html](http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html)

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=

=&gt; e e5+all

E1 0 --> MD-2 Protein/CT  
 E2 152 USE Lymphocyte Antigen 96/CT  
 \*\*\*\*\* END \*\*\*\*\*

=&gt; e e2+all

E1 0 BT4 D Chemicals and Drugs/CT  
 E2 3576 BT3 Biological Factors/CT  
 E3 56387 BT2 Antigens/CT  
 E4 25866 BT1 Antigens, Surface/CT  
 E5 0 BT4 D Chemicals and Drugs/CT  
 E6 0 BT3 Amino Acids, Peptides, and Proteins/CT  
 E7 132344 BT2 proteins/CT  
 E8 79603 BT1 Carrier Proteins/CT  
 E9 152 --> Lymphocyte Antigen 96/CT  
 E10 152 MN D12.776.157.478./CT  
 E11 152 MN D23.50.301.593./CT  
 DC an INDEX MEDICUS major descriptor  
 NOTE A secreted protein that associates with TOLL-LIKE RECEPTOR 4 and is essential for receptor recognition of LIPOPOLYSACCHARIDES.  
 AQ AD AE AG AI AN BI BL CF CH CL CS CT DE DF DU EC GE HI IM IP ME PD PH PK PORE SD SE ST TO TU UL UR  
 HNTE 2006(1999)  
 MHTH NLM (2006)  
 E12 0 UF LY96 Protein/CT  
 E13 0 UF MD-2 Protein/CT  
 \*\*\*\*\* END \*\*\*\*\*

=&gt; fil reg

FILE 'REGISTRY' ENTERED AT 13:37:26 ON 03 JUL 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 2 JUL 2006 HIGHEST RN 890299-71-5  
 DICTIONARY FILE UPDATES: 2 JUL 2006 HIGHEST RN 890299-71-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS  
 for details.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

=> e lymphocyte antigen 96/cn

```
E1      1      LYMPHOCYTE ANTIGEN 86 (SWINE C-TERMINAL FRAGMENT)/CN
E2      1      LYMPHOCYTE ANTIGEN 94 , ACTIVATING NK-RECEPTOR; NK-P46, (MOU
          SE) (HUMAN CLONE MGC:39986 IMAGE:5217510)/CN
E3      0 --> LYMPHOCYTE ANTIGEN 96/CN
E4      1      LYMPHOCYTE ANTIGEN 96 (HUMAN)/CN
E5      1      LYMPHOCYTE ANTIGEN LY-6I.1 (MOUSE S194 CELL GENE LY-6I)/CN
E6      1      LYMPHOCYTE ANTIGEN LY108 (MOUSE STRAIN C57BL/6 SPLEEN GENE L
          Y108 ISOFORM L PRECURSOR)/CN
E7      1      LYMPHOCYTE ANTIGEN LY108 (MOUSE STRAIN C57BL/6 SPLEEN GENE L
          Y108 ISOFORM S PRECURSOR)/CN
E8      1      LYMPHOCYTE ANTIGEN LY6I.2 (MOUSE GENE LY6I PRECURSOR)/CN
E9      1      LYMPHOCYTE ANTIGEN LY75 (HUMAN CLONE WO2005/07667-SEQID-85)/
          CN
E10     1      LYMPHOCYTE CHEMOATTRACTANT FACTOR (HUMAN CLONE LCF-7)/CN
E11     1      LYMPHOCYTE CHEMOATTRACTANT FACTOR (HUMAN CLONE LCF-A)/CN
E12     1      LYMPHOCYTE CHYMASE I/CN
```

=> s e4

```
L1      1 "LYMPHOCYTE ANTIGEN 96 (HUMAN)"/CN
```

=> d l1 sqide3

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 873137-75-8 REGISTRY  
CN **Lymphocyte antigen 96 (human) (9CI)** (CA INDEX NAME)  
OTHER NAMES:  
CN 182: PN: WO2006005035 SEQID: 182 claimed protein  
FS PROTEIN SEQUENCE  
SQL 160

## PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
=====	
Not Given	WO2006005035
	claimed
	SEQID 182

SEQ3 1 Met-Leu-Pro-Phe-Leu-Phe-Phe-Ser-Thr-Leu-  
11 Phe-Ser-Ser-Ile-Phe-Thr-Glu-Ala-Gln-Lys-  
21 Gln-Tyr-Trp-Val-Cys-Asn-Ser-Ser-Asp-Ala-  
31 Ser-Ile-Ser-Tyr-Thr-Tyr-Cys-Asp-Lys-Met-  
41 Gln-Tyr-Pro-Ile-Ser-Ile-Asn-Val-Asn-Pro-  
51 Cys-Ile-Glu-Leu-Lys-Gly-Ser-Lys-Gly-Leu-  
61 Leu-His-Ile-Phe-Tyr-Ile-Pro-Arg-Arg-Asp-  
71 Leu-Lys-Gln-Leu-Tyr-Phe-Asn-Leu-Tyr-Ile-  
81 Thr-Val-Asn-Thr-Met-Asn-Leu-Pro-Lys-Arg-  
91 Lys-Glu-Val-Ile-Cys-Arg-Gly-Ser-Asp-Asp-  
101 Asp-Tyr-Ser-Phe-Cys-Arg-Ala-Leu-Lys-Gly-  
111 Glu-Thr-Val-Asn-Thr-Thr-Ile-Ser-Phe-Ser-  
121 Phe-Lys-Gly-Ile-Lys-Phe-Ser-Lys-Gly-Lys-  
131 Tyr-Lys-Cys-Val-Val-Glu-Ala-Ile-Ser-Gly-  
141 Ser-Pro-Glu-Glu-Met-Leu-Phe-Cys-Leu-Glu-  
151 Phe-Val-Ile-Leu-His-Gln-Pro-Asn-Ser-Asn

## \*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL  
DT.CA CAplus document type: Patent  
RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES  
(Uses)  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil caplus

FILE 'CAPLUS' ENTERED AT 13:38:16 ON 03 JUL 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Jul 2006 VOL 145 ISS 2

FILE LAST UPDATED: 2 Jul 2006 (20060702/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> s 11

L2 1 L1

=> d .ca

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:29606 CAPLUS

DOCUMENT NUMBER: 144:121754

TITLE: Gene expression profile for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine pathways in lung cancer cells

INVENTOR(S): Huang, Fei; Reeves, Karen A.; Han, Xia; Fairchild, Craig R.; Shaw, Peter

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 130 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006005035	A2	20060112	WO 2005-US23687	20050629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006019284	A1	20060126	US 2005-169041	20050628
PRIORITY APPLN. INFO.:			US 2004-584405P	P 20040630

ED Entered STN: 12 Jan 2006

AB The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., lung cell lines, to treatment with compds. that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes,

Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Ephr. These polynucleotides have been shown, through a weighted voting cross validation program, to have utility in predicting the resistance and sensitivity of lung cell lines to the compds. The expression level of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. The Affymetrix human HG-U133 GeneChip set of over 44,792 probe sets was used to identify 129 polynucleotides that are highly correlated with a resistance/sensitivity phenotype classification of 23 lung cell lines subjected to treatment with the protein tyrosine kinase inhibitor compound BMS-A. Of the 129 predictor polynucleotides, 81 polynucleotides highly expressed in the cell lines were classified as sensitive to BMS-A, while 48 polynucleotides highly expressed in the cell lines were classified as resistant to BMS-A. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compds., comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., lung cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process.

CC 1-1 (Pharmacology)

Section cross-reference(s): 3, 6, 14

IT 873136-65-3 873136-67-5, Fibrillin 1 (human) 873136-69-7  
 873136-71-1, Interferon  $\alpha$ -induced protein 27 (human) 873136-74-4,  
 Syndecan 2 (human) 873136-76-6, Glucose transporter SLC2A10 (human)  
 873136-78-8, Promyelocytic leukemia protein (human) 873136-80-2,  
 Transcription factor GATA-6 (human) 873136-82-4, Protein FLJ21313  
 (human) 873136-84-6, Protein FLJ21313 (human) 873136-86-8, Peroxin 6  
 (human) 873136-88-0 873136-90-4, Synaptotagmin-like protein 2 (human)  
 873136-92-6 873136-94-8 873136-96-0 873136-98-2, Epithelial membrane  
 protein 1 (human) 873137-00-9, Integrin  $\alpha$ 3 (human) 873137-03-2,  
 Complement C1s (human) 873137-05-4 873137-07-6, Proteinase, serine, 23  
 (human) 873137-09-8 873137-11-2, Fibroblast growth factor, basic  
 (human) 873137-13-4, Fibroblast growth factor, basic (human)  
 873137-16-7, Ephrin B2 (human) 873137-18-9 873137-20-3 873137-22-5  
 873137-24-7, Retinoic acid-induced protein 3 (human) 873137-27-0,  
 Collagen type XII (human subunit  $\alpha$ 1) 873137-29-2 873137-31-6,  
 Cytochrome P 450 1B1 (human) 873137-34-9, Phosphorylase, uridine (human)  
 873137-37-2, Dehydrogenase, dehydrouracil (human) 873137-39-4,  
 Cytochrome b (human) 873137-41-8, Protein FLJ20073 (human)  
 873137-43-0, Rab13-interacting protein (human) 873137-46-3  
 873137-48-5, Perlecan (human) 873137-50-9, FOS-like antigen 1 (human)  
 873137-52-1, Protein FLJ25348 (human) 873137-54-3 873137-56-5  
 873137-58-7, Protein KIAA0963 (human) 873137-60-1 873137-62-3  
 873137-64-5, Aminopeptidase (human) 873137-66-7 873137-68-9, Myoferlin  
 (human) 873137-71-4, Collagen type VI (human subunit  $\alpha$ 1)  
 873137-73-6 **873137-75-8**, Lymphocyte antigen 96 (human)  
 873137-77-0, Angiopoietin-like 4 protein (human) 873137-79-2, CD44  
 (antigen) (human) 873137-81-6 873137-83-8, Protein KIAA1237 (human)  
 873137-85-0, Protein LOC286167 (human) 873137-87-2 873137-89-4,  
 Protein LOC255104 (human) 873137-91-8, Proteinase, metallo-, ADAMTS-1  
 (human) 873137-93-0 873137-95-2, Antigen Sp100 (human) 873137-97-4,  
 Integrin  $\beta$ 4 (human) 873137-99-6 873138-02-4, Plakophilin 2  
 (human) 873138-04-6 873138-06-8 873138-08-0 873138-10-4,  
 Nucleotidase, 5'- (human) 873138-12-6, Protein KIAA1363 (human)  
 873138-14-8, CD44 (antigen) (human isoform RC) 873138-16-0,

$\alpha$ -Parvin (human) 873138-18-2 873138-20-6 873138-22-8,  
 Neurofilament protein NF-H (human) 873138-24-0 873138-26-2  
 873138-28-4 873138-31-9 873138-33-1, Protein FLJ11869 (human)  
 873138-35-3, Protein FLJ11869 (human) 873138-38-6 873138-40-0, B-cell  
 CLL/lymphoma 11A protein (human) 873138-42-2, LIM homeobox protein 6  
 (human) 873138-45-5, Uncoupling protein 2 (human) 873138-47-7  
 873138-49-9 873138-51-3, Protein p30 (human) 873138-53-5  
 873138-55-7, Galanine (human) 873138-57-9 873138-59-1, Fibroblast  
 growth factor 13 (human) 873138-61-5, J domain-containing protein 1  
 (human) 873138-65-9, Synaptotagmin I (human) 873138-67-1 873138-69-3  
 873138-71-7 873138-73-9 873138-75-1, GABAA receptor (human subunit  
 $\beta$ 3) 873138-77-3, Estrogen-related receptor  $\gamma$  (human)  
 873138-79-5 873138-82-0 873138-84-2, Protein MGC11279 (human)  
 873138-86-4 873138-88-6 873138-90-0 873138-92-2, Protein  
 DKFZp564O1278 (human) 873138-95-5 873138-97-7, Protein KIAA1917  
 (human) 873139-00-5 873139-02-7, NGFI-A binding protein 2 (human)  
 873139-04-9, Protein FLJ37478 (human)  
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP  
 (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (amino acid sequence; gene expression profile for predicting activity  
 of compds. that interact with and/or modulate protein tyrosine kinases  
 and/or protein tyrosine pathways in lung cancer cells)

=> d jos

'JOS' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

ENTER DISPLAY FORMAT (BIB):emd

'EMD' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

ENTER DISPLAY FORMAT (BIB):end

=> log hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	3.53	17.59
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.75	-0.75

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 13:38:51 ON 03 JUL 2006